DDInter1840 DDInter1750
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Trabectedin {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Trabectedin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Prasugrel {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Tazemetostat
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Tazemetostat
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Trabectedin (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Trabectedin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Tazemetostat